Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment. Patients received daratumumab 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570682/
https://ncbi.nlm.nih.gov/pubmed/28637662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-785246
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados